Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
$716,336R01FY2024ARNIH
Brigham And Women'S Hospital, Boston MA
Investigators
Linked publications & trials
Paper 39678346Paper 39486873Paper 39413452Paper 39399289Paper 38996486Paper 38898318Paper 38886003Paper 38706139Paper 38670725Paper 38450423Paper 38448038Paper 38428964Paper 38388169Paper 38360061Paper 38266109Paper 38258675Paper 38199795Paper 38100899Paper 38056314Paper 37956428Paper 37913612Paper 37874643Paper 37873462Paper 37841635Paper 37839812Paper 37701927Paper 37595508Paper 37577493Paper 37506196Paper 37425934Paper 37331741Paper 37192270Paper 36874209Paper 36752280Paper 36656454Paper 36442978Paper 36203557Paper 36118532Paper 36104117Paper 35944947Paper 35909441Paper 35869686Paper 35772415Paper 35765565Paper 35441152
Abstract
PROJECT SUMMARY The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and
View original record on NIH RePORTER →